Quantum BioPharma Readies Lucid-MS for Phase 2 Trials, Unbuzzd Stake Secures $250M Royalties
QNTM•Quantum BioPharma is preparing its patented Lucid-MS therapy to enter phase 2 clinical trials targeting myelin repair in multiple sclerosis patients. The company also holds a 19.84% stake in Unbuzzd Wellness with royalty entitlements of 7% on sales up to $250 million, dropping to 3% thereafter.
1. Lucid-MS Advances to Phase 2 Preparation
Quantum BioPharma's lead candidate, Lucid-MS, is a patented new chemical entity designed to prevent and reverse myelin degradation in multiple sclerosis. Following successful preclinical results, the company is moving this first-in-class therapy into phase 2 clinical trials to assess safety and efficacy in patients.
2. Unbuzzd Stake and Royalty Structure
Through its spin-out Unbuzzd Wellness, Quantum holds a 19.84% equity stake and royalty rights. The agreement grants 7% of Unbuzzd’s sales until cumulative payments reach $250 million, after which royalties drop to 3% in perpetuity, supporting long-term revenue potential.
